



05-09-02

1642

Patent Docket P1150R2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

P#4

In re Application of  Avi J. Ashkenazi et al.  Serial No.: 10/080455  Filed: February 22, 2002  For: DNA 19355 Polypeptide, A Tumor Necrosis Factor Homolog	Group Art Unit: 1642  Examiner: not yet assigned  <div><p>CERTIFICATE OF EXPRESS MAILING</p><p>Express Mail Number: <u>EL 889 343 451 US</u></p><p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents, Washington, D.C. 20231."</p><p>May <u>7</u>, 2002</p><p><i>Mona Beltran</i></p><p>Mona Beltran</p></div>
--	--

TRANSMITTAL LETTER

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Information Disclosure Statement
2. Form 1449 with 0 References
3. Postcard

RECEIVED  
MAY 15 2002  
TECH CENTER 1600/2900

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: May 7, 2002

By:

*Diane L. Marschang*  
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE  
#110367



Patent Docket P1150R2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Avi J. Ashkenazi et al.  Serial No.: 10/080455  Filed: February 22, 2002  For: DNA 19355 Polypeptide, A Tumor Necrosis Factor Homolog	Group Art Unit: 1642  Examiner: not yet assigned  <b>CERTIFICATE OF EXPRESS MAILING</b> Express Mail Number: <u>EL 889 343 451 US</u>  I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to "Assistant Commissioner of Patents, Washington, D.C. 20231."  May <u>7</u> , 2002  <i>Mona Beltran</i> Mona Beltran
--	---

**RECEIVED**  
MAY 15 2002  
TECH CENTER 1600/2300

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/195,368, filed November 18, 1998 and relied upon in this application for an earlier filing date under 35 USC §120.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

Serial No.: 10/080455  
Filed: February 22, 2002

Page 3

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: May 7, 2002

By: Diane L. Marschang  
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE  
#110321



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1150R2C1Serial No.  
10/080,455

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
22 Feb 2002Group  
1642

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	5,998,171	07.12.99	Yu et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	* 2	307,247 B1	15.03.89	EPO			
	* 3	417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)			
	* 4	WO 97/01633	16.01.97	PCT			
	* 5	WO 98/06842	19.02.98	PCT			
	* 6	WO 98/07880	26.02.98	PCT			

RECEIVED  
MAY 15 2002  
TECH CENTER 1600/2900

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 7	Aggarwal et al., "Tumor Necrosis Factors: Development During the Last Decade" <u>Eur. Cytokine Netw.</u> 7(2):93-124 (April- Ju 1996)
* 8	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-Induced Death of Developing T Cells" <u>Symposium on Programmed Cell Death</u> (Abstract No. 10), Cold Spring Harbor Laboratory (1995)
* 9	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40" <u>Nature</u> 357(6373):80-82 (1992)
* 10	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
* 11	Baeuerle et al., "Function and activation of NF-kappa B in the immune system" <u>Ann. Rev. Immunol.</u> 12:141-179 (1994)
* 12	Baldwin, A., "The NF-kB and IKB Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
* 13	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF $\beta$ Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
* 14	Barr and Tomei, "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
* 15	Baum et al., "Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34" <u>EMBO Journal</u> 13(17):3992-4001 (1994)
* 16	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
* 17	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)
* 18	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)
* 19	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
* 20	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

MAY 07 2002

Sheet 2 of 6

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1150R2C1Serial No.  
10/080,455

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
AshkenaziFiling Date  
22 Feb 2002Group  
1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |      |  |
|------|--|
| * 21 | Browning et al., "Lymphotoxin $\beta$ , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface" <u>Cell</u> 72:847-856 (1993)  |
| * 22 | Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)   |
| * 23 | Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)   |
| * 24 | Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)                                |
| * 25 | Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)   |
| * 26 | Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)   |
| * 27 | Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)   |
| * 28 | Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- $\gamma$ " <u>European Journal of Immunology</u> 17:689-693 (1987)  |
| * 29 | Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (1997)                                   |
| * 30 | Eck and Sprang, "The structure of tumor necrosis factor- $\alpha$ at 2.6 Å resolution" <u>Journal of Biological Chemistry</u> 264(29):17595-17605 (1989)   |
| * 31 | Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)   |
| * 32 | Fraser and Evan, "A License to Kill" <u>Cell</u> 85:781-784 (1996)   |
| * 33 | Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)                               |
| * 34 | Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)   |
| * 35 | Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular &amp; Cellular Biology</u> 11:3020-3026 (1991)                                       |
| * 36 | Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)  |
| * 37 | Gruss, H.J. et al., "Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily" <u>Int. J. Clin. Lab. Res</u> 26(3):143-159 (1996)   |
| * 38 | Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991) |
| * 39 | Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF $\alpha$ )" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)                              |
| * 40 | Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <u>Cell</u> 84:299-308 (1996)  |

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

FORM PTO-1449

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1150R2C1Serial No.  
10/080,455Applicant  
AshkenaziFiling Date  
22 Feb 2002Group  
1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |      |   |
|------|---|
| * 41 | Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)   |
| * 42 | Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)  |
| * 43 | Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)  |
| * 44 | Klein et al., "Selection for Genes Encoding Secreted Proteins and Receptors" <u>Proc. Natl. Acad. Sci. USA</u> 93(14):7108-7113 (1996)  |
| * 45 | Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)  |
| * 46 | Kozak, "An analysis of vertebrate mRNA sequences: intimations of translational control" <u>Journal of Cell Biology</u> 115:887-903 (1991)   |
| * 47 | Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)   |
| * 48 | Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)  |
| * 49 | Lewit-Bentley et al., "Structure of tumour necrosis factor by X-ray solution scattering and preliminary studies by single crystal X-ray diffraction" <u>J. Mol. Biol.</u> 199(2):389-392 (1988)   |
| * 50 | Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)  |
| * 51 | MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997)   |
| * 52 | MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- $\alpha$ Activation" <u>J. Immunol.</u> 153:5274-5284 (1994)  |
| * 53 | Malinin et al., "MAP3K-related kinase involved in NF- $\kappa$ B induction by TNF, CD95 and IL-1" <u>Nature</u> 385(6616):540-544 (February 6, 1997)  |
| * 54 | Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - A Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9(4):1063-1068 (April 1990)   |
| * 55 | Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)  |
| * 56 | Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- $\kappa$ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)   |
| * 57 | Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- $\kappa$ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997) |
| * 58 | Marsters et al., "Interferon $\gamma$ Signals Via a High-Affinity Multisubunit Receptor Complex That Contains Two Types of Polypeptide Chain" <u>Proc. Natl. Acad. Sci. USA</u> 92:5401-5405 (1995)   |
| * 59 | Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)   |
| * 60 | Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)   |

Date Considered

Examiner

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1150R2C1Serial No.  
10/080,455

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi

Filing Date

22 Feb 2002

Group

1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


* 61	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
* 62	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
* 63	Nocentini et al., "A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis" <u>Proc. Natl. Acad. Sci.</u> 94(12):6216-6221 (1997)
* 64	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
* 65	O'Reilley et al. <u>Baculovirus Expression Vectors: A Laboratory Manual</u> , Oxford:Oxford University Press (1994)
* 66	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
* 67	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL." <u>Science</u> . 276:111-113 (Apr 4, 1997)
* 68	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)
* 69	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
* 70	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
* 71	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)
* 72	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 $\beta$ Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)
* 73	Ruppert et al., "Cloning and Expression of Human TAF <sub>II</sub> 250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993)
* 74	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)
* 75	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)
* 76	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
* 77	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
* 78	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor $\alpha$ inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
* 79	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
* 80	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





RECEIVED  
MAY 15 2002  
TECH CENTER 1000900

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1150R2C1

Serial No.

10/080,455

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi

Filing Date

22 Feb 2002

Group

1642

OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

* 81	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
* 82	Smith et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen" <u>Science</u> 238:1704-1707 (1987)
* 83	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. &amp; Biophys. Res. Comm.</u> 176:335-342 (1991)
* 84	Sompayrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7575-7578 (Dec 1981)
* 85	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
* 86	Steller, H., "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)
* 87	Takahashi et al., "Human Fas ligand: gene structure, chromosomal location and species specificity" <u>Int. Immunol.</u> 6(10):1567-1574 (1994)
* 88	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
* 89	Tartaglia et al., "A novel domain within the 55 kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)
* 90	Tewari and Dixit, "Fas- and Tumor Necrosis Factor-induced Apoptosis is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)
* 91	Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)
* 92	Tewari et al., "Yama/ CPP32 $\beta$ , a Mammalian Homolog of CED-3, is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)
* 93	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982)
* 94	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)
* 95	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
* 96	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)
* 97	Verma et al., "Rel/NF-kB/IkB Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
* 98	von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (1997)
* 99	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)
*100	Wang et al., "Ich-1, and Ice/ced-3-Related Gene, Encodes Both Positive and Negative Regulators of Programmed Cell Death" <u>Cell</u> 78:739-750 (September 9, 1994)

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce  
Patent and Trademark Office

Serial No.  
10/080,455

Applicant  
Ashkenazi

Filing Date  
22 Feb 2002

Group	1642
-------	------

[illegible]

Date Considered

USCOMM-DC 80-398.